Partial Truncation of the C-Terminal Domain of PTCH1 in Cancer Enhances Autophagy and Metabolic Adaptability.
ATG101
Hedgehog
PTCH1
autophagy
cancer
glycolysis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Jan 2023
06 Jan 2023
Historique:
received:
02
12
2022
revised:
30
12
2022
accepted:
30
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
The Hedgehog receptor, Patched1 (PTCH1), is a well-known tumour suppressor. While the tumour suppressor's activity is mostly ascribed to its function as a repressor of the canonical Smoothened/Gli pathway, its C-terminal domain (CTD) was reported to have additional non-canonical functions. One of them is the reduction of autophagic flux through direct interaction with the Unc-51, like the autophagy activating kinase (ULK) complex subunit autophagy-related protein-101 (ATG101). With the aim of investigating whether this function of PTCH1 is important in cancer cell fitness, we first identified frameshift mutations in the CTD of PTCH1 in cancer databases. We demonstrated that those mutations disrupt PTCH1 interaction with ATG101 and increase autophagic flux. Using deletion mutants of the PTCH1 CTD in co-immunoprecipitation studies, we established that the 1309-1447 region is necessary and sufficient for interaction with ATG101. We next showed that the three most common PTCH1 CTD mutations in endometrial, stomach and colon adenocarcinomas that cause frameshifts at S1203, R1308 and Y1316 lack the ability to interact with ATG101 and limit autophagic flux, determined by bafilomycin A1-sensitive accumulation of the autophagy markers LC3BII and p62. We next engineered PTCH1 indel mutations at S1223 by CRISPR/Cas9 in SW620 colon cancer cells. Comparison of two independent clones harbouring PTCH1 S1223fs mutations to their isogenic parental cell lines expressing wild-type PTCH1 showed a significant increase in basal and rapamycin-stimulated autophagic flux, as predicted by loss of ATG101 interaction. Furthermore, the PTCH1 CTD mutant cells displayed increased proliferation in the presence of rapamycin and reduced sensitivity to glycolysis inhibitors. Our findings suggest that loss of the PTCH1-ATG101 interaction by mutations in the CTD of PTCH1 in cancer might confer a selective advantage by stimulating autophagy and facilitating adaptation to nutrient deprivation conditions.
Identifiants
pubmed: 36672319
pii: cancers15020369
doi: 10.3390/cancers15020369
pmc: PMC9856372
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S01716X/1
Pays : United Kingdom
Organisme : Italian Association for Cancer Research
ID : IG25833
Organisme : Istituto Pasteur
ID : Fondazione Cenci Bolognetti
Organisme : Sapienza University of Rome
ID : RG12117A61923A6F
Organisme : Dipartimenti di Eccellenza
ID : L. 232/2016
Organisme : Fondazione Umberto Veronesi
ID : fellowship to L.D.M
Références
Nat Cell Biol. 2009 Jun;11(6):739-46
pubmed: 19465923
EMBO J. 2015 Apr 1;34(7):856-80
pubmed: 25712477
Nature. 2001 May 17;411(6835):349-54
pubmed: 11357142
Cell Death Differ. 2005 Nov;12 Suppl 2:1542-52
pubmed: 16247502
Genes Dev. 2006 Sep 15;20(18):2539-51
pubmed: 16980583
Cells. 2022 Feb 03;11(3):
pubmed: 35159339
Eur J Cancer. 2006 Mar;42(4):437-45
pubmed: 16406505
Nat Rev Cancer. 2012 Apr 26;12(6):401-10
pubmed: 22534666
Int J Mol Sci. 2017 Aug 28;18(9):
pubmed: 28846632
Sci Signal. 2015 Jun 02;8(379):ra55
pubmed: 26038600
Nat Genet. 2016 Apr;48(4):398-406
pubmed: 26950094
Trends Genet. 2021 Mar;37(3):235-250
pubmed: 33272592
Mol Cancer Res. 2018 May;16(5):909-919
pubmed: 29453315
Mol Cell Biol. 2014 Oct;34(20):3855-66
pubmed: 25092867
Cell Res. 2014 Jan;24(1):42-57
pubmed: 24343578
Vitam Horm. 2012;88:55-72
pubmed: 22391299
Sci Signal. 2012 Oct 16;5(246):re6
pubmed: 23074268
Angew Chem Int Ed Engl. 2005 May 6;44(19):2852-69
pubmed: 15880548